Mission
Our mission is to facilitate the clinical implementation of precision medicine by improving patient outcomes through the optimization of efficacy and limiting toxicity of drug therapy. This is accomplished through research, teaching and service focused on genetically-guided therapeutic decision-making, drug discovery and drug development.
Goals
- Enhance the quality of precision medicine through pharmacogenomics research
- Bring together faculty working in the precision medicine field and increase multidisciplinary collaboration among faculty
- Provide genotyping, gene expression, DNA methylation, and analytical services to the UF community and beyond
- Provide an environment for training clinical and translational scientists in pharmacogenomics
- Educate the UF Health community on pharmacogenomics
Services
Pharmacogenomic laboratory and analytical services are provided for UF and non-UF investigators through the CPPM Core Laboratory. Services are provided either as a price per sample or price per project depending on the service type and specific needs of the researcher. Researchers interested in multiple services will be provided with an estimate of the charges for the entire project. We strive to accommodate the needs of each researcher; if you do not see a service listed on our menu, please inquire.
GENOTYPING
Services and Pricing
Review our services, state-of-the-art technology, and pricing.
Leadership
Co Directors
Larisa H Cavallari Pharm.D., BCPS, FCCP
Julio D Duarte Pharm.D., Ph.D., FAHA
Director of Genotyping Core Lab
Taimour Langaee MSPH, Ph.D.
Affiliated Faculty | Research Interests
Associate Dean For Accessibility, Belonging And Community Health; Clinical Associate Professor
John Allen, Pharm.D., BCPS, BCCCP, FCCM, FCCP
* Antibiotic resistance
* Cancer survivorship
* Health disparities and Social determinants of health
* Health disparities and vulnerable populations
* Sepsis
Professor and the Debbie DeSantis Term Professor in the UF College of Pharmacy
Larisa Cavallari, Pharm.D.
* Effectiveness of cardiovascular drugs
* Dose requirements of warfarin
* Opioid effectiveness and toxicity
* Drug metabolism enzyme activity and expression
* Outcomes with clinical implementation of genotype-guided therapy
Clinical Associate Professor
Emily Cicali, Pharm.D.
* Drug metabolism enzyme activity and expression
* Outcomes with clinical implementation of genotype-guided therapy
Associate Professor
Rhonda Cooper-DeHoff, Pharm.D., M.S.
* Effectiveness of cardiovascular drugs
* Outcomes with clinical implementation of genotype-guided therapy
Clinical Professor
David DeRemer, Pharm.D.
* Cancer treatment outcomes
* Cardiotoxic response to cancer treatments (Cardio-Oncology)
Associate Professor
Julio Duarte, Pharm.D., Ph.D.
* Effectiveness of cardiovascular drugs
* Genomics to identify novel drug targets for cardiopulmonary diseases
* Outcomes with clinical implementation of genotype-guided therapy
Assistant Professor
Mohammed Gbadamosi, Ph.D.
* Personalized medicine
* Immuno-oncology
* Cancer disparities
* Metastatic cancer
* Big data analytics
Associate Professor
Yan Gong, Ph.D.
* Effectiveness of cardiovascular drugs
* Cardiotoxic response to cancer treatments (Cardio-Oncology)
* Adverse drug response to antiresorptive drugs
Distinguished Professor
Julie Johnson, Pharm.D.
* Effectiveness of cardiovascular drugs
* Dose requirements of warfarin
* Opioid effectiveness and toxicity
* Drug metabolism enzyme activity and expression
* Outcomes with clinical implementation of genotype-guided therapy
Associate Dean For Research And Graduate Education; Professor And The Frank A. Duckworth Eminent Scholar Chair
Jatinder Lamba, Ph.D., M.Sc.
* Cancer treatment outcomes
* Toxicity to anti-leukemic agents
* CRISPR/cas9 mediated genetic perturbation screening in cancer
* Development of genomics guided immunotherapy for treatment of leukemia
* Systems biology approaches using multi-dimensional data to establish prognostic markers in cancer
Research Professor
Taimour Langaee, Ph.D., MSPH
* Response to treatment for HIV, TB, HBV and other infectious diseases
* Response to dichloroacetate treatment in children with lactic acidosis
Professor
John Markowitz, Pharm.D.
* Drug metabolism enzyme activity and expression
* Drug transporter activity
Assistant Professor
Caitrin McDonough, Ph.D., M.S.
* Effectiveness of cardiovascular drugs
* Predisposition to adverse cardiovascular and cerebrovascular outcomes and high risk disease
* Development of multi-dimensional data models for cardiovascular disease identification and prediction
* Development of multi-dimensional data models for Alzheimer’s Disease and Related Dementias
Clinical Assistant PRofessor
Khoa Nguyen, Pharm.D.
* Effectiveness of cardiovascular drugs
* Opioid effectiveness and toxicity
* Outcomes with clinical implementation of genotype-guided therapy
Associate Professor
Luisel Ricks-Santi, Ph.D.
* Cancer treatment options
* Predisposition to aggressive breast and prostate cancer
* Genetic basis of cancer disparities
* Outcomes with clinical implementation of genotype-guided therapy
Clinical Assistant Professor
Nathan Seligson, Pharm.D.
* Cancer treatment options
* Systems biology approaches using multi-dimensional data to establish prognostic markers in cancer
ASSOCIATE PROFESSOR
Danxin Wang, M.D. Ph.D.
* Drug metabolism enzyme activity and expression
CHIEF OF THE DIVISION OF CARDIOLOGY AND MEDICAL DIRECTOR OF THE UF HEALTH CARDIOVASCULAR CENTER
Dominick Angiolillo, M.D., Ph.D.
* Effectiveness of cardiovascular drugs
Professor
Awewura Kwara, M.D., M.B., ChB, M.P.H., TM
* Response to treatment for HIV, TB, HBV and other infectious diseases
Policies and Forms
Download policies and forms related to the Center for Pharmacogenomics and Precision Medicine
